Yu S, Yeh cr, Niu Y, Chang hc

1. 
   Yu S, Yeh CR, Niu Y, Chang HC, Tsai YC, Moses HL, Shyr CR, Chang C, Yeh S.: Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate. 2012 Mar;72(4):437-49.
   
2. 
   Xu D, Lin TH, Zhang C, Tsai YC, Li S, Zhang J, Yin M, Yeh S, Chang C. The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells. Prostate. 2012 May 15;72(7):803-16.
   
3. 
   Huang KH, Kuo KL, Chen SC, Weng TI, Chuang YT, Tsai YC, Pu YS, Chiang CK, Liu SH. Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PLoS One. 2012;7(3):e33615. Epub 2012 Mar 16.
   
4. 
   Pu YS, Huang CY, Chen JY, Kang WY, Lin YC, Shiu YS, Chuang SJ, Yu HJ, Lai MK, Tsai YC, Wu WJ, Hour TC. Down-regulation of PKCζ in renal cell carcinoma and its clinicopathological implications. J Biomed Sci. 2012 Apr 5;19:39.
   
5. 
   Tsai YC, Yeh CH, Tzen KY, Ho PY, Tuan TF, Pu YS, Cheng AL, Cheng JC. Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signaling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. Eur J Cancer. 2013 Apr;49(6):1458-66
   
6. 
   Tai HC, Chang AC, Yu HJ, Huang CY, Tsai YC, Lai YW, Sun HL, Tang CH, Wang SW. Osteoblast-derived Wnt-1-induced secreted protein 1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126. Oncotarget. 2014 Sep 15;5(17):7589-98.
   
7. 
   Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 2014 Sep 15;5(17):7917-35
   
8. 
   Tsai YC, Ho PY, Tzen KY, Tuan TF, Liu WL, Cheng AL, Pu YS, Cheng JC. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells. Mol Cancer Ther. 2015 Mar;14(3):810-20.
   
9. 
   Hu CY, Tsai YC, Wang SM, Huang CY, Tai HC, Chen CH, Pu YS, Lin WC, Huang KH. Ureteral involvement and diabetes increase the risk of subsequent bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Biomed Res Int. 2015;2015:527976. Epub 2015 Mar 31.
   
10. 
    Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai YC, Chang HC, Chou CT, Hsu CH, Hsieh JT, Chang SC, Pu YS, Huang KH. MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer Lett. 2015 Jul 28;363(2):127-36.
    
11. 
    Ho IL, Kuo KL, Liu SH, Chang HC, Hsieh JT, Wu JT, Chiang CK, Lin WC, Tsai YC, Chou CT, Hsu CH, Pu YS, Shi CS, Huang KH. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma. Sci Rep. 2015 Nov 23;5:16948
    
12. 
    Hsu FM, Hou WH, Huang CY, Wang CC, Tsai CL, Tsai YC, Yu HJ, Pu YS, Cheng JC. Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. Chronobiol Int. 2016;33(2):210-9.